Compass Therapeutics (CMPX) Stock Price, News, Quotes-Moomoo

Account Info

Log Out

US Stock MarketDetailed Quotes

CMPX Compass Therapeutics

Watchlist

1.965
0.0000.00%

Close Oct 14 16:00 ET

2.020
+0.055+2.80%

Pre 09:27 ET

270.36MMarket Cap-5614P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

No Data

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
GlobeNewswireOct 4 10:31 ET
Compass Therapeutics Analyst Ratings
BenzingaSep 16 09:24 ET · Ratings
Ladenburg Thalmann Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Cuts Target Price to $5
Moomoo NewsSep 16 07:31 ET · Ratings
Ladenburg Thalmann Upgrades Compass Therapeutics to Buy From Neutral
MT NewswiresSep 16 07:17 ET
Compass Therapeutics to Participate in Upcoming Investor Events
Yahoo FinanceSep 3 08:00 ET
Express News | Compass Therapeutics Inc. Files for Mixed Shelf of up to $300 Mln - SEC Filing
ReutersAug 30 17:24 ET

Comments

Jaguar8

Oct 4 10:42

NEWS

$Compass Therapeutics (CMPX.US)$
Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
Compass Therapeutics (Nasdaq: CMPX), a clinical-stage oncology-focused biopharmaceutical company, announced the acceptance of an abstract for poster presentation at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting. The meeting will be held from November 8–10, 2024, in Houston, TX.
The poster presentation, titled 'Pharmaco...

Jaguar8

Apr 16 07:02

$Compass Therapeutics (CMPX.US)$
NEWS
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
Compass Therapeutics dosed the first patient in the Phase 1 trial of CTX-8371, a novel dual checkpoint blocker targeting PD-1 and PD-L1 in patients with solid tumors. The study aims to evaluate the drug's efficacy in patients who failed prior checkpoint blocker treatments.

Moomoo Breakfast US

May 4, 2022 07:22

Columns Today's pre-market stock movers: AMD, SBUX, ABNB, MRNA and more

Gainers:
• $Livent (LTHM.US)$ +22.58% (it posted better-than-expected quarterly earnings and raised its 2022 revenue forecast)
• $Super Micro Computer (SMCI.US)$ +11.01% (earnings reports)
• $Oatly Group AB (OTLY.US)$ +8.31% (earnings reports)
• $BlueLinx Holdings (BXC.US)$ +9.7% (increases share repurchase authorization to $100 mln; enters into $60 mln accelerated repurchase agreement)
• $Starbucks (SBUX.US)$ +7.18% (matched estimates wi...

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

CMPX Compass Therapeutics

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target